Tonix Pharmaceuticals Holding Corp (TNXP)

[subslover]

Talk about your cash burn rate =====HOLY SHIT!
Results of Operations and Financial Condition.


Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended June 30, 2022, and certain preliminary financial condition information as of June 30, 2022, as set forth below:



• The Company ended the second quarter with approximately $145.5 million in cash and cash equivalents, and shares of common stock outstanding of 31,692,024 at June 30, 2022.
• Net loss for the three and six months ended June 30, 2022, is expected to be approximately $23.1 million and $49.6 million, respectively, compared to $23.6 million and $44.2 million for the three and six months entered June 30, 2021, respectively.
• The Company’s net cash used in operating activities for the six months ended June 30, 2022, was approximately $52.2 million compared to $40.2 million for the six months ended June 30, 2021.
• The Company’s capital expenditures for the six months ended June 30, 2022, was approximately $34.7 million compared to $1.9 million for the six months ended June 30, 2021.
• The Company’s equity proceeds from the sale of common stock for the six months ended June 30, 2022, was approximately $58.0 million compared to $130.7 million for the six months ended June 30, 2021.
• As of July 29, 2022, the Company had 35,861,957 shares of common stock outstanding.


The above information is preliminary financial information for the second quarter of 2022 and subject to completion. The unaudited, estimated results for the second quarter of 2022 are preliminary and were prepared by the Company’s management, based upon its estimates, a number of assumptions and currently available information, and are subject to revision based upon, among other things, quarter-end closing procedures and/or adjustments, the completion of the Company’s interim consolidated financial statements and other operational procedures. This preliminary financial information is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not completed its financial closing procedures for the quarter ended June 30, 2022, and its actual results could be materially different from this preliminary financial information, which preliminary information should not be regarded as a representation by the Company or its management as to its actual results for quarter ended June 30, 2022. In addition, EisnerAmper LLP, the Company’s independent registered public accounting firm, has not audited, reviewed, compiled, or performed any procedures with respect to this preliminary financial information and does not express an opinion or any other form of assurance with respect to this preliminary financial information. During the course of the preparation of the Company’s financial statements and related notes as of and for the quarter ended June 30, 2022, the Company may identify items that would require it to make material adjustments to this preliminary financial information. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles and reviewed by the Company’s auditors.



The Company currently expects to file its Quarterly Report on Form 10-Q includ

[Value_Investor]

TNXP just a New high $2.22! We should see $4.79 again as soon as next Monday...

$1.18 will be the Bottom!

[weedtrader420]

WEEEEEEEEEEEEEEE WOOHOOOOOO $5 TARGET

[subslover]

Currently trading 2's

[MASTERULTRA]

Sweet baby jesus. TNXP CLOSED ABOVE 50MA... hell yeah

[subslover]

And another nice climb for Tonix. Some nice after-hours trading as well :)

[Pt3]

Nope tnxp fail since. Pandemic hit

[Value_Investor]

Hopefully today's Good News will push TNXP back to $4.79 again...

[subslover]

Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
July 28 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-8011 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.
“We are excited to collaborate with KEMRI on the clinical development of TNX-801 as a vaccine to protect against monkeypox and smallpox in Kenya,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Since ending routine vaccination for smallpox in the 1960’s, monkeypox has emerged as a growing problem among people in West and Central Africa. People who received the live virus vaccine for smallpox prior to eradication appear to maintain durable protective immunity against monkeypox. TNX-801 is a live virus vaccine that we believe is closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines. TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox.”

“KEMRI is excited to plan this clinical trial with Tonix, and ultimately to lead the trial,” said Professor Samuel Kariuki, Director General and CEO of KEMRI. “Monkeypox has spread in Central and West Africa, and there’s a concern that we could begin seeing cases in the Eastern and Central Africa or from foreign travelers. Recently, monkeypox has been reported in over 30 countries outside of Africa that were not endemic for monkeypox virus. We are grateful that Tonix is committed to sponsoring clinical studies and making TNX-801 available for this important problem.”

Professor Matilu Mwau, PhD, of KEMRI said, “The recent global outbreak of monkeypox has exemplified the need to be prepared with a vaccine that is efficacious, that provides for durable immunity and that blocks forward transmission. Tonix’s live virus vaccine technology is designed to achieve these outcomes. The West African strain which has recently spread outside of Africa has a low fatality rate, but the Central African strain is reportedly fatal in approximately 10% of infected individuals. We want Kenya to be prepared with a vaccine that provides protection and can be widely deployed without the need for sterile injections or ultra-cold shipping and storage.”

About TNX-801

TNX-801 is a live virus vaccine based on synthesized horsepox2,3. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. TNX-801 was developed as part of research collaboration between Tonix and Professor David Evans, Ph.D. and Ryan Noyce, Ph.D., the Department of Cell Biology, University of Alberta. Tonix has previously reported positive data from a monkeypox challenge study in non-human primates4. Tonix’s TNX-801 was synthesized2 based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763. Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 17986-8. For example, recent studies9,10 have shown approximately 99.7% colinear identity between TNX-801 and the circa 1860 U.S. smallpox vaccine VK0511. The small plaque size in culture of TNX-801 appears identical to the U.S. Centers for Disease Control publication of the natural isolate12. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Dr. Edward Jenner invented vaccination in 1798 and the procedure was called “vaccination” because ‘cow’ is ‘vacca’ in Latin and the inoculum material was initially obtained from lesions on the udders of cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8. Subsequently, Dr. Jenner and others immunized against smallpox using material directly obtained from horses. The use of vaccines from horses was sometimes called ‘equination’ from the Latin ‘equus’ which means ‘horse’13. Equination and vaccination were practiced side-by-side in Europe13,14.

About Monkeypox

Monkeypox15 is a contagious disease caused by infection with monkeypox virus, a virus closely related to variola virus, which causes smallpox. Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus. After routine smallpox vaccination was stopped in about 1970, monkeypox has become a growing problem in Africa. Recently more than 16,000 cases have been identified outside of Africa17.

About the Kenya Medical Research Institute (KEMRI)

The Kenya Medical Research Institute is a State Corporation established in 1979 as a Research Institute under the Science and Technology (Repealed) Act, Cap 250 Laws of Kenya and operates as such under Legal Notice No. 35 of March 2021. KEMRI’s vision is to be the leading centre of excellence in research for human health. The mission is to improve human health and quality of life through research, capacity building, innovation and service delivery. KEMRI has grown from its humble beginning over 40 years ago to become a regional leader in human health research. KEMRI is the Medical Research arm of the Government of Kenya.

[weedtrader420]

TNXP$ Dance Monkey

[weedtrader420]

TNXP$ WOOHOOOOOO Rockin Robin

[Value_Investor]

Wow, TNXP surged to $2.08 so far! So we might see the most recent high $4.79 again as soon as tomorrow, instead of breaking down $1.18 to hit $0.15 again!

Hopefully it could run the Same 5.2-Bagger to hit $6.136 as the peer (PBHG) --- from 0.0005 to 0.0026 most recently!

[subslover]

2's trading!!!!!! SWEET!

[subslover]

Pushing hard towards $2.00

[weedtrader420]

WEeeeeeeeeeeeee

[weedtrader420]

Should be fun tomorrow TNXP

[XWAVXALMIMAN]

Anyone hear the Seth Lederman interview today?

Skip to 27 minutes. This why we traded over 53 million shares today with only 31.69 million shares outstanding.

Tonix has $140 million in the bank and no debt- that’s 4.42 per share. We are grossly undervalued

[weedtrader420]

WOOHOOOOOO

[subslover]

Anything is possible but I doubt it drops below $1.00 :)

[weedtrader420]

TNXP$

[Value_Investor]

Will TNXP bounce back to $4.79 again or it will further crash to Pre-R/S Bottom $0.15 again?

[subslover]

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development
July 25 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development. In this role, Dr. Bavari will be responsible for leading Tonix’s development of its growing infectious disease pipeline and will serve as a key member of the Company’s executive leadership team. Dr. Bavari will be based in Frederick, Md. and, as part of his role, will oversee scientific development at Tonix’s Infectious Disease R&D Center located there.
“We are delighted that Dr. Bavari has joined our team to lead our infectious disease research and development efforts,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “Dr. Bavari has a proven track record of innovation and of developing scientific strategies as well as leading programs at all stages of discovery and development.”

“I am excited to join Tonix and to lead the Company's efforts in infectious disease research and development programs, including vaccines in development for monkeypox, smallpox and COVID-19,” said Dr. Bavari. “The Frederick, Md. Research and Development Center, or RDC, is a state-of-the-art facility with exceptional capabilities. The facility is up and running and is staffed by an outstanding team of scientists. I look forward to leveraging my years of experience in industry and government to expedite this important work with the goal of ultimately solving health problems on a global basis.”

Dr. Bavari has a record of achievement utilizing new and complex technologies and in guiding programs through clinical decision points into advanced development. He is an inventor of approximately 30 patents, published over 300 peer-reviewed manuscripts and contributed to 15 development candidates, as well as numerous Investigational New Drug candidate filings. Most recently, he served as Chief Scientific Officer / Scientific Director at the U.S. Army Research Institute of Infectious Diseases (USAMRIID) and has held numerous leadership roles at USAMRIID, including Chief, Molecular and Translational Sciences Division and Therapeutic Discovery Center; Chief, Target Discovery & Experimental Microbiology, Integrated Toxicology Division; and Chief, Immunology, Target Identification, and Translational Research, Bacteriology Division. Dr. Bavari earned his Ph.D. in Immunotoxicology and Pharmaceutical Science at the University of Nebraska Medical Center in Omaha, Neb., and his M.S. in Nuclear Physics and Nuclear Pharmacy at the University of Southern California, Los Angeles.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is mid-Phase 2 and has been granted Breakthrough Therapy Designation by the FDA. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-D

[Value_Investor]

Another New 52-week-low $1.53 was created last week! TNXP will hit Pre-R/S Bottom $0.15 again in the coming days/weeks before Another TOXIC Big R/S...

[XWAVXALMIMAN]

Why did CEO buy 20,000 shares at 1.71 and why did someone invest $30 million recently?

https://www.streetinsider.com/dr/news.php?id=11765760&gfv=1

https://ir.tonixpharma.com/news-events/press-releases/detail/1326/tonix-pharmaceuticals-announces-pricing-of-30-million

[Value_Investor]

New 52-week-low $1.62 so far! TNXP will hit Pre-R/S Bottom $0.15 again in the coming days/weeks before Another TOXIC Big R/S...

Sell the Biggest Pos Scam (TNXP) ASAP then use all the cash proceeds to buy a Super-Undervalued Pink-Sheet Hidden Gem at Basement to recover our Huge losses here since an excellent OTC stock can easily run 5 ~ 50-Bagger or more (such as PBHG: it did run 55-Bagger and 5.2-Bagger respectively)!

[Pennyes]

hope folks read this news between lines carefully, preferred stocks sold at a price of some $4s!?. and they can convert preferred at this issued price after certain timeline, however, this notice and press release comes at a time, the stock was just rallied upto this offering price and crashed below $2, is this not deceptive and fraudulant?.. did they bring down the price from 4-to under 2 to sell prefferred stock?...numerous questions arises by TNXPs shoddy, shaddy behaviors..!. bstds should be put in jail.

[subslover]

Tonix Pharma (TNXP) Prices $30M Convertible Redeemable Preferred Stock Placement
https://www.streetinsider.com/Corporate+News/Tonix+Pharma+%28TNXP%29+Prices+%2430M+Convertible+Redeemable+Preferred+Stock+Placement/20240318.html

[stockmavin]

Write a book about it.

[Value_Investor]

The Pos Scam just created another New low $1.63 last week! More New lows come very soon until it hits $0.15 again...

[stockmavin]

Yyyaaaawwwwnnnnnn

[Value_Investor]

This Repeated-Big-R/S & Endless-Super-Heavy-Diluting NASDAQ Pos Scam (TNXP) will crash to a New low $0.8046 from previous Bottom $4.8 since its NASDAQ peer (TBLT) had already crashed down to $3.52 so far from its previous Bottom $21!

The only hope here is, after TNXP hits its Final Bottom we might see a Quick 5.2-Bagger Huge rally to hit $4.18392 like its OTC peer (PBHG) did (from $0.0005 to $0.0026) most recently...

[stockmavin]

Much larger scams out there. Do your research.

[Value_Investor]

The Biggest NASDAQ Pos Scam (TNXP) will crash to a New low $0.9508 from previous Bottom $4.8 since its NASDAQ peer had already crashed down to $4.16 so far from previous Bottom $21!

Why this Biggest Pos Scam (TNXP) shows the FAKE OS count (15,507,674 shares on 05/17/2022) from its TA on the otcmarkets.com while TNXP actually had 18,739,988 shares OS after the 1:32 Big R/S?

https://www.otcmarkets.com/stock/TNXP/security

Who bought TNXP at $4.79 ~ $4.0 last week? Why? TNXP needs to run a 5.2-bagger Huge rally like its OTC peer did (on 12/30/2021) in order to hit $4.94416 from Bottom $0.9508! Otherwise we won't see $4.xx again in the future!

So we all should liquidate this Biggest Pos Scam (TNXP) ASAP then use all the cash proceeds to buy a Bottomed-Out OTC peer at $0.000x to recover our Huge losses here...

[Homebrew]

Reverse Split to stay on NASDAQ ?

[Pennyes]

I still stand on what I said last week, SEC must shut down TNXP
"must be SHUT Down" , it is a Scam and ponzhi schemers are behind this company and nasdaq!...gullible shareholders loose everything while ponzhi schmers fill their pockets!.

[Pennyes]

do not worry my friend, no body is blaming you, its all good,
shareholders must know what is going on out there!, that news confirms that the whole thing TNXP did is to get that notice, until next crash and another R/S and rinse, repeat activities...!.

[Pennyes]

since nasdag sent a letter, along with blood thirsty suckers called "Shorters", tnxp almost lost 50% (more than $2 from its rally two days ago?), it took 5 years to run up $2 above usual trading and but took only two days to loose it?........what kind of criminals are running stock market?

[subslover]

I really don't know. Just reporting the news.

[Pennyes]

Nasdaq scam!?...compliance garbage...!.
So the TNXP mafia did R/S and buy back stunt, just TO keep the price above $1 for 10 days so they receive this nasdaq bullshit!....nasdaq is a big scammer than TNXP!

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

[gattes12]

Pretty soon we're going to start seeing the suckers who bought in at $4 begin the pumpity pump and tell you what a great company this is having not paid any attention to it before they thought it was going to squeeze.

[subslover]

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHATHAM, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 1, 2022, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, Tonix’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.

[dinogreeves]

Another scam from the past, 162 million in volume and only up 24%. Shame, this is going to bite the dust too. Always has been a scam, thus always will be.

[renaissance1]

I agree 100%. Total BS to do that to your shareholders. Wiped us all out right before big event. Absolutely terrible.

[Value_Investor]

The Biggest NASDAQ Pos Scam (TNXP) will crash to $1.0103 from previous Bottom $4.8 since its peer had already crashed down to $4.42 so far from previous Bottom $21!

[THEMASTERS_SON]

,,,,,,,NEXT 8K-FILING $12M-SHAREBUYBACK. WEEEEEE!

[THEMASTERS_SON]

,,,,,,,18M/OS $12M BUYBACK…U GETTING ROCKED!!!!

[Bronk]

Cause this stock looks like a steaming pile of shit. Anyone investing here is getting rocked. Flip it and that’s it

[THEMASTERS_SON]

Thanks for the $2’s MORON

[THEMASTERS_SON]

WRONG

[bcapps66]

And why is that funny?